To address this, we developed a LbL NP combination therapy that utilizes tumor‐targeting chemistry to deliver a synergistic dose of BCL2/XLi (ABT‐263) and MCL1i (S63845) therapy to solid tumor cells. This evidence concerns the gene BCL2 and neoplasm.